289 related articles for article (PubMed ID: 31969375)
1. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
Cristea S; Coles GL; Hornburg D; Gershkovitz M; Arand J; Cao S; Sen T; Williamson SC; Kim JW; Drainas AP; He A; Cam LL; Byers LA; Snyder MP; Contrepois K; Sage J
Cancer Res; 2020 Mar; 80(6):1293-1303. PubMed ID: 31969375
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
3. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
4. YAP promotes myogenic differentiation
Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
[TBL] [Abstract][Full Text] [Related]
5. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
7. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
8. Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development.
Nishimoto S; Kusakabe M; Nishida E
EMBO Rep; 2005 Nov; 6(11):1064-9. PubMed ID: 16179948
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-dependent regulation of MEKK2/3-MEK5-ERK5 signaling module by XIAP and cIAP1.
Takeda AN; Oberoi-Khanuja TK; Glatz G; Schulenburg K; Scholz RP; Carpy A; Macek B; Remenyi A; Rajalingam K
EMBO J; 2014 Aug; 33(16):1784-801. PubMed ID: 24975362
[TBL] [Abstract][Full Text] [Related]
10. The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target.
Simões AE; Rodrigues CM; Borralho PM
Drug Discov Today; 2016 Oct; 21(10):1654-1663. PubMed ID: 27320690
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
12. The MEK5/ERK5 mitogen-activated protein kinase cascade is an effector pathway of bone-sustaining bisphosphonates that regulates osteogenic differentiation and mineralization.
Adam C; Glück L; Ebert R; Goebeler M; Jakob F; Schmidt M
Bone; 2018 Jun; 111():49-58. PubMed ID: 29567200
[TBL] [Abstract][Full Text] [Related]
13. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation.
Raviv Z; Kalie E; Seger R
J Cell Sci; 2004 Apr; 117(Pt 9):1773-84. PubMed ID: 15075238
[TBL] [Abstract][Full Text] [Related]
14. Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.
Broustas CG; Duval AJ; Chaudhary KR; Friedman RA; Virk RK; Lieberman HB
Oncogene; 2020 Mar; 39(12):2467-2477. PubMed ID: 31980741
[TBL] [Abstract][Full Text] [Related]
15. Non-redundant function of the MEK5-ERK5 pathway in thymocyte apoptosis.
Sohn SJ; Lewis GM; Winoto A
EMBO J; 2008 Jul; 27(13):1896-906. PubMed ID: 18548009
[TBL] [Abstract][Full Text] [Related]
16. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation.
Nakamura K; Uhlik MT; Johnson NL; Hahn KM; Johnson GL
Mol Cell Biol; 2006 Mar; 26(6):2065-79. PubMed ID: 16507987
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic signaling of MEK5-ERK5.
Hoang VT; Yan TJ; Cavanaugh JE; Flaherty PT; Beckman BS; Burow ME
Cancer Lett; 2017 Apr; 392():51-59. PubMed ID: 28153789
[TBL] [Abstract][Full Text] [Related]
18. MEK5/ERK5 pathway: the first fifteen years.
Drew BA; Burow ME; Beckman BS
Biochim Biophys Acta; 2012 Jan; 1825(1):37-48. PubMed ID: 22020294
[TBL] [Abstract][Full Text] [Related]
19. MEK5 and ERK5 are mediators of the pro-myogenic actions of IGF-2.
Carter EJ; Cosgrove RA; Gonzalez I; Eisemann JH; Lovett FA; Cobb LJ; Pell JM
J Cell Sci; 2009 Sep; 122(Pt 17):3104-12. PubMed ID: 19654213
[TBL] [Abstract][Full Text] [Related]
20. MEK5 is activated by shear stress, activates ERK5 and induces KLF4 to modulate TNF responses in human dermal microvascular endothelial cells.
Clark PR; Jensen TJ; Kluger MS; Morelock M; Hanidu A; Qi Z; Tatake RJ; Pober JS
Microcirculation; 2011 Feb; 18(2):102-17. PubMed ID: 21166929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
